Obesity Abstracts

The area of genetic causes of syndromic and non-syndromic obesity has a large unmet clinical need to treat underlying hyperphagia. In recent years, improved understanding of underlying mechanisms resulting from the underlying gene(s) defects has revealed potential therapeutic targets, while designation of orphan disease has promoted the interest of biotechnology and pharmaceutical companies for these rare genetic obesities. This talk will review the emerging trial data on the ...

Obesity pharmacotherapy has had a difficult history, with many challenges, and some effective medicines withdrawn due to safety concerns. More recently, better understanding of the biological mechanisms underlying body weight regulation have led to development of more effective treatments, some of which are now entering clinical use. These include treatments for single gene disorders, such as metreleptin for the rare condition of leptin deficiency, and setmelanotide for pro-op...

Post bariatric surgery care within the NHS is currently for 2 years. Post bariatric surgery hypoglycaemia (PBSH) can occur many years following surgery. The true prevalence of symptomatic PBSH is difficult to establish given variable recording and high median time to first event following surgery. Screening post-operative patients reveals high rates of asymptomatic hypoglycaemia of uncertain significance. The numbers of symptomatic patients fulfilling Whipple’s triad is s...

The objective of SOPHIA is to optimise future obesity treatment. This has been challenging because too often, clinicians, payers and patients do not consider obesity a disease. SOPHIA proposes that obesity is in fact a set of complex and chronic diseases that should be taken just as seriously as other heterogeneous chronic conditions. We define diseases of obesity in the context of (a) the risks of complications linked to obesity and (b) the responses the diseases have to vari...